Anja Bilandzic1, Laura Rosella1,2,3. 1. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 2. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 3. Public Health Ontario, Toronto, Ontario, Canada.
Abstract
INTRODUCTION: Our objective was to estimate the future direct health care costs due to diabetes for a 10-year period in Canada using national survey data, a validated diabetes risk prediction tool and individual-level attributable cost estimates. METHODS: We used the Diabetes Population Risk Tool to predict the number of new diabetes cases in those aged 20 years and above over a 10-year period (to 2022), using 2011 and 2012 Canadian Community Health Survey data. We derived attributable costs due to diabetes from a propensity-matched case control study using the Ontario Diabetes Database and other administrative data. We calculated total costs by applying the respective attributable costs to the incident cases, accounting for sex, year of diagnosis and annual disease-specific mortality rates. RESULTS: The predicted 10-year risk of developing diabetes for the Canadian population in 2011/12 was 9.98%, corresponding to 2.16 million new cases. Total health care costs attributable to diabetes during this period were $7.55 billion for females and $7.81 billion for males ($15.36 billion total). Acute hospitalizations accounted for the greatest proportion of costs (43.2%). A population intervention resulting in 5% body weight loss would save $2.03 billion in health care costs. A 30% risk-reduction intervention aimed at individuals with the highest diabetes risk (i.e. the top 10% of the highest-risk group) would save $1.48 billion. CONCLUSION: Diabetes represents a heavy health care cost burden in Canada through to the year 2022. Our future cost calculation method can provide decision makers and planners with an accessible and transparent tool to predict future expenditures attributable to the disease and the corresponding cost savings associated with interventions.
INTRODUCTION: Our objective was to estimate the future direct health care costs due to diabetes for a 10-year period in Canada using national survey data, a validated diabetes risk prediction tool and individual-level attributable cost estimates. METHODS: We used the Diabetes Population Risk Tool to predict the number of new diabetes cases in those aged 20 years and above over a 10-year period (to 2022), using 2011 and 2012 Canadian Community Health Survey data. We derived attributable costs due to diabetes from a propensity-matched case control study using the Ontario Diabetes Database and other administrative data. We calculated total costs by applying the respective attributable costs to the incident cases, accounting for sex, year of diagnosis and annual disease-specific mortality rates. RESULTS: The predicted 10-year risk of developing diabetes for the Canadian population in 2011/12 was 9.98%, corresponding to 2.16 million new cases. Total health care costs attributable to diabetes during this period were $7.55 billion for females and $7.81 billion for males ($15.36 billion total). Acute hospitalizations accounted for the greatest proportion of costs (43.2%). A population intervention resulting in 5% body weight loss would save $2.03 billion in health care costs. A 30% risk-reduction intervention aimed at individuals with the highest diabetes risk (i.e. the top 10% of the highest-risk group) would save $1.48 billion. CONCLUSION:Diabetes represents a heavy health care cost burden in Canada through to the year 2022. Our future cost calculation method can provide decision makers and planners with an accessible and transparent tool to predict future expenditures attributable to the disease and the corresponding cost savings associated with interventions.
Entities:
Keywords:
Canada; attributable cost; diabetes; economics; incidence; prediction model
Authors: Keith G Dawson; Daniel Gomes; Hertzel Gerstein; James F Blanchard; Kristijan H Kahler Journal: Diabetes Care Date: 2002-08 Impact factor: 19.112
Authors: Laura C Rosella; Douglas G Manuel; Charles Burchill; Thérèse A Stukel Journal: J Epidemiol Community Health Date: 2010-06-01 Impact factor: 3.710
Authors: Richard H Glazier; Maria I Creatore; Jonathan T Weyman; Ghazal Fazli; Flora I Matheson; Peter Gozdyra; Rahim Moineddin; Vered Kaufman-Shriqui; Vered Kaufman Shriqui; Gillian L Booth Journal: PLoS One Date: 2014-01-14 Impact factor: 3.240
Authors: L C Rosella; M Lebenbaum; T Fitzpatrick; D O'Reilly; J Wang; G L Booth; T A Stukel; W P Wodchis Journal: Diabet Med Date: 2015-08-19 Impact factor: 4.359
Authors: Megan M MacPherson; Kaela D Cranston; Sean R Locke; Jessica E Bourne; Mary E Jung Journal: Transl Behav Med Date: 2021-08-13 Impact factor: 3.046
Authors: John J Miklavcic; Kimberly D Fraser; Jenny Ploeg; Maureen Markle-Reid; Kathryn Fisher; Amiram Gafni; Lauren E Griffith; Sandra Hirst; Cheryl A Sadowski; Lehana Thabane; Jean A C Triscott; Ross Upshur Journal: BMC Geriatr Date: 2020-05-13 Impact factor: 3.921
Authors: Elizabeth Alvarez; Majdi Qutob; Lawrence Mbuagbaw; John Lavis; Cynthia Lokker; Marjan Walli-Attaei; Zainab Samaan; Arielle Sutton; Japteg Singh; David Feeny; John Fortuna Journal: BMJ Open Date: 2019-10-16 Impact factor: 2.692